Form 4: BioCryst Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

BioCryst Pharmaceuticals Director Steven Frank acquired 333 shares of common stock on May 30, 2025, as part of his board member compensation.

Summary

• Director Steven Frank acquired 333 shares of BioCryst Pharmaceuticals Inc. common stock.
• The transaction occurred on May 30, 2025.
• The shares were acquired at a price of $10.75 per share.
• This acquisition was in lieu of 100% of his prorated quarterly cash Board Member retainer, valued at $3,585.
• Following this transaction, Mr. Frank beneficially owns 2,199 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director in lieu of cash compensation is generally viewed positively as it aligns management's interests with shareholders, indicating confidence in the company's future.

Positives

• Director Steven Frank increased his direct ownership in BioCryst Pharmaceuticals by acquiring 333 shares.
• The acceptance of shares instead of cash for compensation aligns the director's interests more closely with shareholders.

Negatives

• No direct negative financial implications are apparent from this compensation-related transaction.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This Form 4 filing is a disclosure of an insider transaction and does not contain information suitable for comparison to industry-specific financial or operational benchmarks.

Related Party Transactions

• Director Steven Frank received 333 shares of common stock in lieu of a prorated quarterly cash Board Member retainer of $3,585, representing a transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders may view the director's decision to accept shares instead of cash for compensation as a positive sign of alignment with shareholder interests.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Pharmaceuticals, Biotech